5duq
From Proteopedia
(Difference between revisions)
												
			
			| Line 3: | Line 3: | ||
| <StructureSection load='5duq' size='340' side='right'caption='[[5duq]], [[Resolution|resolution]] 2.90Å' scene=''> | <StructureSection load='5duq' size='340' side='right'caption='[[5duq]], [[Resolution|resolution]] 2.90Å' scene=''> | ||
| == Structural highlights == | == Structural highlights == | ||
| - | <table><tr><td colspan='2'>[[5duq]] is a 2 chain structure with sequence from [ | + | <table><tr><td colspan='2'>[[5duq]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5DUQ OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=5DUQ FirstGlance]. <br> | 
| - | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=BGC:BETA-D-GLUCOSE'>BGC</scene>, <scene name='pdbligand=GLC:ALPHA-D-GLUCOSE'>GLC</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene>, <scene name='pdbligand= | + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.9Å</td></tr> | 
| - | + | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=BGC:BETA-D-GLUCOSE'>BGC</scene>, <scene name='pdbligand=GLC:ALPHA-D-GLUCOSE'>GLC</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene>, <scene name='pdbligand=PRD_900023:alpha-cellobiose'>PRD_900023</scene>, <scene name='pdbligand=SO3:SULFITE+ION'>SO3</scene></td></tr> | |
| - | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=5duq FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5duq OCA], [https://pdbe.org/5duq PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=5duq RCSB], [https://www.ebi.ac.uk/pdbsum/5duq PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=5duq ProSAT]</span></td></tr> | |
| - | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[ | + | |
| </table> | </table> | ||
| == Disease == | == Disease == | ||
| - | [ | + | [https://www.uniprot.org/uniprot/IC1_HUMAN IC1_HUMAN] Defects in SERPING1 are the cause of hereditary angioedema (HAE) [MIM:[https://omim.org/entry/106100 106100]; also called hereditary angioneurotic edema (HANE). HAE is an autosomal dominant disorder characterized by episodic local subcutaneous edema and submucosal edema involving the upper respiratory and gastrointestinal tracts. HAE due to C1 esterase inhibitor deficiency is comprised of two clinically indistinguishable forms. In HAE type 1, representing 85% of patients, serum levels of C1 esterase inhibitor are less than 35% of normal. In HAE type 2, the levels are normal or elevated, but the protein is non-functional.<ref>PMID:12773530</ref> <ref>PMID:7814636</ref> <ref>PMID:3178731</ref> <ref>PMID:2365061</ref> <ref>PMID:2296585</ref> <ref>PMID:2118657</ref> [:]<ref>PMID:1451784</ref> <ref>PMID:1363816</ref> <ref>PMID:8172583</ref> <ref>PMID:7883978</ref> <ref>PMID:8529136</ref> <ref>PMID:8755917</ref> <ref>PMID:14635117</ref> <ref>PMID:16409206</ref> <ref>PMID:22994404</ref>  | 
| == Function == | == Function == | ||
| - | [ | + | [https://www.uniprot.org/uniprot/IC1_HUMAN IC1_HUMAN] Activation of the C1 complex is under control of the C1-inhibitor. It forms a proteolytically inactive stoichiometric complex with the C1r or C1s proteases. May play a potentially crucial role in regulating important physiological pathways including complement activation, blood coagulation, fibrinolysis and the generation of kinins. Very efficient inhibitor of FXIIa. Inhibits chymotrypsin and kallikrein.<ref>PMID:8495195</ref>  | 
| <div style="background-color:#fffaf0;"> | <div style="background-color:#fffaf0;"> | ||
| == Publication Abstract from PubMed == | == Publication Abstract from PubMed == | ||
| Line 26: | Line 25: | ||
| __TOC__ | __TOC__ | ||
| </StructureSection> | </StructureSection> | ||
| - | [[Category:  | + | [[Category: Homo sapiens]] | 
| [[Category: Large Structures]] | [[Category: Large Structures]] | ||
| - | [[Category: Dijk | + | [[Category: Dijk M]] | 
| - | [[Category: Giannetti | + | [[Category: Giannetti BM]] | 
| - | [[Category: Holkers | + | [[Category: Holkers J]] | 
| - | [[Category: Pannu | + | [[Category: Pannu NS]] | 
| - | + | [[Category: Voskamp P]] | |
| - | [[Category: Voskamp | + | [[Category: Waterreus WJ]] | 
| - | [[Category: Waterreus | + | [[Category: Van Veen HA]] | 
| - | [[Category:  | + | |
| - | + | ||
| - | + | ||
Current revision
Active human c1-inhibitor in complex with dextran sulfate
| 
 | |||||||||||
